VIR Biotechnology and Gilead Sciences have formed a collaboration and licensing agreement to develop new Pro-Xten® dual-masked T-cell engagers targeting solid tumors.

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.